Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(12 sites)
United States
Stanford University School of Medicine, Palo Alto, California Therapeutics Clinical Research, San Diego, California Yale Center for Clinical Investigation, New Haven, Connecticut Northwestern Dermatology CTU, Chicago, Illinois Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana